Group-II metabotropic glutamate receptor ligands as adjunctive drugs in the treatment of depression: A new strategy to shorten the latency of antidepressant medication?

Molecular Psychiatry

Volumn 12, Issue 8, 2007, Pages 704-706

  Matrisciano, F ^a,b   Panaccione, I ^a   Zusso, M ^c   Giusti, P ^c   Tatarelli, R ^b   Iacovelli, L ^a   Mathe A A ^d   Gruber, S H M ^d   Nicoletti, F ^a,e   Girardi, P ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e IRCCS NEUROMED   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 4 PHOSPHONOPHENYLGLYCINE; [(2 METHYL 1,3 THIAZOL 4 YL)ETHYNYL]PYRIDINE; [3 (3,4 DICHLOROBENZYLOXY) 2 AMINO 6 FLUOROBICYCLO]HEXANE 2,6 DICARBOXYLIC ACID 6 HEPTYL ESTER; CLOMIPRAMINE; CYCLOLEUCINE; FLUOXETINE; IMIPRAMINE; IONOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENYL 7 (HYDROXYIMINO)CYCLOPROPANE[B]CHROMEN 1A CARBOXAMIDE; UNCLASSIFIED DRUG;

ATAXIA; CELL PROLIFERATION; DISEASE SEVERITY; DRUG TARGETING; HUMAN; LATENT PERIOD; LEARNING DISORDER; LETTER; MAJOR DEPRESSION; MEMORY DISORDER; NONHUMAN; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; SUICIDE ATTEMPT; SYNAPTIC TRANSMISSION;

ADJUVANTS, PHARMACEUTIC; AMINO ACIDS; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BICYCLO COMPOUNDS, HETEROCYCLIC; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID AGENTS; HIPPOCAMPUS; IMIPRAMINE; MICE; NEURONS; RATS; RATS, INBRED STRAINS; RECEPTOR CROSS-TALK; RECEPTORS, METABOTROPIC GLUTAMATE; TIME FACTORS; XANTHENES;

EID: 34547397923     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/sj.mp.4002005     Document Type: Letter

References (16)

1. Li X, Need AB, Baez M, Witkin JM. J Pharmacol Exp Ther 2006; 319: 254-259.
2. Alt A, Nisenbaum ES, Bleakman D, Witkin JM. Biochem Pharmacol 2006; 71: 1273-1288.
3. Palucha A, Pilc A. Drugs News Perspect 2005; 18: 262-268.
4. Javitt DC. Mol Psychiatry 2004; 9: 984-997, , 979.
5. Lee JM, Zipfel GJ, Choi DW. Nature 1999; 399: A7-A14.
6. Nicoletti F, Meek JL, Iadarola MJ, Chuang DM, Roth BL, Costa E. J Neurochem 1986; 46: 40-46.
7. Bruno V, Battaglia G, Copani A, D'Onofrio M, Di Iorio P, De Blasi et al. J Cereb Blood Flow Metab 2001; 2: 1013-1033.
8. Pin JP, Duvoisin R. Neuropharmacology 1995; 34: 1-26.
9. Schoepp DD, Jane DE, Monn JA. Neuropharmacology 1999; 38: 1431-1476.
10. Palucha A. Expert Opin Investig Drugs 2006; 15: 1545-1553.
11. Cryan JF, Kelly PH, Neijt HC, Sansig G, Flor JP, Van Der Putten H. Eur J Neurosci 2003; 17: 2409-2417.
12. Matrisciano F, Scaccianoce S, Del Bianco P, Panaccione I, Canudas AM, Battaglia G et al. J Neurochem 2005; 93: 1345-1352.
13. Matrisciano F, Storto M, Ngomba RT, Cappuccio I, Caricatole A, Scaccianoce S et al. Neuropharmacology 2002; 42: 1008-1015.
14. Zusso M, Debetto P, Guidolin D, Giusti P. Crit Rev Neurobiol 2004; 16: 59-65.
15. Overstreet DH, Friedman E, Mathé AA, Yadid G. Neurosci Biobehav Rev 2005; 29: 739-759.
16. Schiller GD, Pucilowski O, Wienicke C, Overstreet DH. Brain Res Bull 1992; 28: 821-823.